Related Experiment Video
Updated: Feb 7, 2026

Metacarpal Small Incision for Carpal Tunnel Syndrome
Published on: April 5, 2024
Tourniquet Use in Wide-Awake Carpal Tunnel Release
Sarah E Sasor1, Julia A Cook1, Stephen P Duquette1
1Indiana University, Indianapolis, USA.
Abstract:
Background: Carpal tunnel syndrome is a common cause of upper extremity discomfort. Surgical release of the median nerve can be performed under general or local anesthetic, with or without a tourniquet. Wide-awake carpal tunnel release (CTR) (local anesthesia, no sedation) is gaining popularity. Tourniquet discomfort is a reported downside. This study reviews outcomes in wide-awake CTR and compares tourniquet versus no tourniquet use. Methods: Wide-awake, open CTRs performed from February 2013 to April 2016 were retrospectively reviewed. Patients were divided into 2 cohorts: with and without tourniquet. Demographics, comorbidities, tobacco use, operative time, estimated blood loss, complications and outcomes were compared. Results: A total of 304 CTRs were performed on 246 patients. The majority of patients were male (88.5%), and the mean age was 59.9 years. One hundred patients (32.9%) were diabetic, and 92 patients (30.2%) were taking antithrombotics. Seventy-five patients (24.7%) were smokers. A forearm tourniquet was used for 90 CTRs (29.6%). Mean operative time was 24.97 minutes with a tourniquet and 21.69 minutes without. Estimated blood loss was 3.16 mL with a tourniquet and 4.25 mL without. All other analyzed outcomes were not statistically significant. Conclusion: Operative time was statistically longer and estimated blood loss was statistically less with tourniquet use, but these findings are not clinically significant. This suggests that local anesthetic with epinephrine is a safe and effective alternative to tourniquet use in CTR. The overall rate of complications was low, and there were no major differences in postoperative outcomes between groups.
Related Concept Videos
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
ATP Energy Storage and Release
One example of energy coupling using ATP involves a...
Drugs Affecting Neurotransmitter Release or Uptake
In Vitro Drug Release Testing: Overview, Development and Validation
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

